BAG3 down-modulation reduces anaplastic thyroid tumor growth by enhancing proteasome-mediated degradation of BRAF protein

Journal of Clinical Endocrinology and Metabolism

Volumn 97, Issue 1, 2012, Pages

  Chiappetta, Gennaro ^a   Basile, Anna ^a,b   Arra, Claudio ^a   Califano, Daniela ^a,b   Pasquinelli, Rosa ^a   Barbieri, Antonio ^a,b   De Simone, Veronica ^a   Rea, Domenica ^a   Giudice, Aldo ^a   Pezzullo, Luciano ^a   De Laurenzi, Vincenzo ^c   Botti, Gerardo ^a   Losito, Simona ^a   Conforti, Daniela ^a,b   Turco, Maria Caterina ^b  

^a NATIONAL CANCER INSTITUTE   (Italy)

^b UNIVERSITY OF SALERNO   (Italy)

^c UNIVERSITY OF CHIETI   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOVIRUS VECTOR; B CELL LYMPHOMA 2 ASSOCIATED ATHANOGENE 3 PROTEIN; B RAF KINASE; CHAPERONE; PROTEASOME; SMALL INTERFERING RNA; UNCLASSIFIED DRUG;

ANAPLASTIC CARCINOMA; ANAPLASTIC THYROID TUMOR; ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; CANCER INHIBITION; CONTROLLED STUDY; DOWN REGULATION; FEMALE; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOPRECIPITATION; IN VITRO STUDY; IN VIVO STUDY; INCUBATION TIME; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN DEGRADATION; THYROID TUMOR; TUMOR GROWTH; VIRAL GENE DELIVERY SYSTEM;

ADAPTOR PROTEINS, SIGNAL TRANSDUCING; ANIMALS; CELL GROWTH PROCESSES; CELL LINE, TUMOR; DOWN-REGULATION; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MICE; MICE, NUDE; PROTEASOME ENDOPEPTIDASE COMPLEX; PROTEIN BINDING; PROTEOLYSIS; PROTO-ONCOGENE PROTEINS B-RAF; RNA, SMALL INTERFERING; THYROID NEOPLASMS; UP-REGULATION; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84855514725     PISSN: 0021972X     EISSN: 19457197     Source Type: Journal    
DOI: 10.1210/jc.2011-0484     Document Type: Article

References (20)

1. Jemal A, Siegel R, Ward E, Murray T, Xu J, Thun MJ 2007 Cancer statistics. CA Cancer J Clin 57:43-66
2. Verdecchia A, Francisci S, Brenner H, Gatta G, Micheli A, Mangone L, Kunkler I 2007 Recent cancer survival in Europe: a 2000-02 period analysis of EUROCARE-4 data. Lancet Oncol 8:784-796
3. Pacini F, Schlumberger M, Dralle H, Elisei R, Smit JW, Wiersinga W 2006 European consensus for the management of patients with differentiated thyroid carcinoma of the follicular epithelium. Eur J Endocrinol 154:787-803
4. Nucera C, Porrello A, Antonello ZA, Mekel M, Nehs MA, Giordano TJ, Gerald D, Benjamin LE, Priolo C, Puxeddu E, Finn S, Jarzab B, Hodin RA, Pontecorvi A, Nose V, Lawler J, Parangi S 2010 B-Raf(V600E) and thrombospondin-1 promote thyroid cancer progression. Proc Natl Acad Sci USA 107:10649-10654
5. Ouyang B, Knauf JA, Smith EP, Zhang L, Ramsey T, Yusuff N, Batt D, Fagin JA 2006 Inhibitors of Raf kinase activity block growth of thyroid cancer cells with RET/PTC or BRAF mutations in vitro and in vivo. Clin Cancer Res 12:1785-1793
6. Pratilas CA, Solit DB 2010 Targeting the mitogen-activated protein kinase pathway: physiological feedback and drug response. Clin Cancer Res 16:3329-3334
7. Rosati A, Graziano V, De Laurenzi V, Pascale M, Turco MC 2011 BAG3: a multifaceted protein that regulates major cell pathways. Cell Death Dis 2:e141
8. Chiappetta G, Ammirante M, Basile A, Rosati A, Festa M, Monaco M, Vuttariello E, Pasquinelli R, Arra C, Zerilli M, Todaro M, Stassi G, Pezzullo L, Gentilella A, Tosco A, Pascale M, Marzullo L, Belisario MA, Turco MC, Leone A 2007 The antiapoptotic protein BAG3 is expressed in thyroid carcinomas and modulates apoptosis mediated by tumor necrosis factor-related apoptosis-inducing ligand. J Clin Endocrinol Metab 92:1159-1163
9. Ammirante M, Rosati A, Arra C, Basile A, Falco A, Festa M, Pascale M, d'Avenia M, Marzullo L, Belisario MA, De Marco M, Barbieri A, Giudice A, Chiappetta G, Vuttariello E, Monaco M, Bonelli P, Salvatore G, Di Benedetto M, Deshmane SL, Khalili K, Turco MC, Leone A 2010 IKKγ protein is a target of BAG3 regulatory activity in human tumor growth. Proc Natl Acad Sci USA 107:7497-7502
10. Mead R 1988 The design of experiments: statistical principles for practical applications. New York: Cambridge University Press
11. Hosmer DW, Lemeshow S, May S 2008 Applied survival analysis: regression modeling of time-to-event data. 2nd ed. Hoboken, NJ: John Wiley, Sons
12. Leboeuf R, Baumgartner JE, Benezra M, Malaguarnera R, Solit D, Pratilas CA, Rosen N, Knauf JA, Fagin JA 2008 BRAFV600E mutation is associated with preferential sensitivity to mitogen-activated protein kinase kinase inhibition in thyroid cancer cell lines. J Clin Endocrinol Metab 93:2194-2201
13. Davies H, Bignell GR, Cox C, Stephens P, Edkins S, Clegg S, Teague J, Woffendin H, Garnett MJ, Bottomley W, Davis N, Dicks E, Ewing R, Floyd Y, Gray K, Hall S, Hawes R, Hughes J, Kosmidou V, Menzies A, Mould C, Parker A, Stevens C, Watt S, Hooper S, et al. 2002 Mutations of the BRAF gene in human cancer. Nature 417: 949-954
14. Satyamoorthy K, Li G, Gerrero MR, Brose MS, Volpe P, Weber BL, Van Belle P, Elder DE, Herlyn M 2003 Constitutive mitogen-activated protein kinase activation in melanoma is mediated by both BRAF mutations and autocrine growth factor stimulation. Cancer Res 63:756-759
15. Balmanno K, Cook SJ 2009 Tumour cell survival signalling by the ERK1/2 pathway. Cell Death Differ 16:368-377
16. Lassalle S, Hofman V, Ilie M, Butori C, Bozec A, Santini J, Vielh P, Hofman P 2010 Clinical impact of the detection of BRAF mutations in thyroid pathology: potential usefulness as diagnostic, prognostic and theragnostic applications. Curr Med Chem 17:1839-1850
17. Giacinti C, Giordano A 2006 RB and cell cycle progression. Oncogene 25:5220-5227
18. Flaherty KT 2010 Narrative review: BRAF opens the door for therapeutic advances in melanoma. Ann Intern Med 153:587-591
19. Siena S, Sartore-Bianchi A, Di Nicolantonio F, Balfour J, Bardelli A 2009 Biomarkers predicting clinical outcome of epidermal growth factor receptor-targeted therapy in metastatic colorectal cancer. J Natl Cancer Inst 101:1308-1324
20. von Deimling A, Korshunov A, Hartmann C 2011 The next generation of glioma biomarkers: MGMT methylation, BRAF fusions and IDH1 mutations. Brain Pathol 21:74-87